X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
IT Riluzole (riluzole)is a intrathecally delivered glutamate antagonist. It is being evaluated for the treatment of amyotrophic lateral sclerosis & other central nervous system diseases.
Lead Product(s): Riluzole
Therapeutic Area: Neurology Product Name: IT-Riluzole
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
AB1010 (masitinib) is a tyrosine kinase inhibitor, small molecule drug. It is being evaluated in phase 3 clinical studies in combination with Rilutek (riluzole) for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2024
Details:
AB1010 (masitinib) is a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. It downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces neuroprotection.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
The proceeds will be used to fund the development of AB1010 (masitinib) for the treatment of amyotrophic lateral sclerosis and the development of the microtubule destabilizer agents (MDA) platform, with the clinical development of AB8939 in refractory acute myeloid leukemia.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 24, 2023
Details:
AB1010 (masitinib), a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. It downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces neuroprotection.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Clinigen confirms that Proleukin, interleukin-2 (aldesleukin), supplied for the MIROCALS trial, is currently licensed for metastatic renal cell carcinoma and melanoma in the US and metastatic renal cell carcinoma in certain other countries.
Lead Product(s): Aldesleukin,Riluzole
Therapeutic Area: Neurology Product Name: Proleukin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Long-term follow-up survival data showing a significant benefit in favor of Alsitek (masitinib) in moderate ALS patients (between group difference in median OS of +25 months, hazard ratio 0.56 (95%CI [0.32;0.96])).
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: Alsitek
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
This agreement with Haisco will allow ALS patients in China to access EXSERVAN, a riluzole oral film, which will provide a meaningful treatment option to those who have to discontinue their treatment because of difficulties swallowing a tablet.
Lead Product(s): Riluzole
Therapeutic Area: Neurology Product Name: Exservan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Haisco Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $7.0 million
Deal Type: Licensing Agreement March 03, 2022
Details:
AB1010 (masitinib), a selective tyrosine kinase inhibitor, modulates the activity of mast cells and macrophages in patients for the treatment of ALS, and is currently developed in three therapeutic areas: neurology, inflammatory diseases and oncology.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Details:
Study AB10015 previously showed that masitinib (4.5 mg/kg/day) as an add-on to standard riluzole, significantly slowed functional decline at week 48 relative to those treated with riluzole alone.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2022
Details:
Masitinib is a orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2021
Details:
The allowed claims cover the combination of MN-166 (ibudilast) and riluzole for use in a method of treating a patient with ALS wherein the treatment results in stabilization of the patient’s scleroses state.
Lead Product(s): Ibudilast,Riluzole
Therapeutic Area: Neurology Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2021
Details:
MediciNova has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): Ibudilast,Riluzole
Therapeutic Area: Neurology Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
Study AB19001 is an international Phase 3 study to compare the efficacy and safety of masitinib in combination with riluzole vs placebo in combination with riluzole in ALS.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
